Movymia | European Medicines Agency (EMA)

April 25, 2025

[ad_1]

Overview

This is a summary of the European public assessment report (EPAR) for Movymia. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Movymia.

For practical information about using Movymia, patients should read the package leaflet or contact their doctor or pharmacist.

Movymia is a medicine used for the treatment of osteoporosis (a disease that makes bones fragile) in:

women who have been through the menopause. In these patients, Movymia has been shown to significantly reduce vertebral (spine) and non-vertebral fractures (broken bones), but not those of the hip;
men who are at an increased risk of fractures;
men and women who are at an increased risk of fractures due to long-term treatment with glucocorticoids (a type of steroid).

Movymia contains the active substance teriparatide.

Movymia is a ‘biosimilar medicine’. This means that Movymia is highly similar to a biological medicine (also known as the ‘reference medicine’) that is already authorised in the European Union (EU). The reference medicine for Movymia is Forsteo. For more information on biosimilar medicines, see the question-and-answer document here.

Movymia is available as a solution for injection in cartridges (containing 600 micrograms of teriparatide) intended to be used with ServoPen Fix system. The recommended dose is 20 micrograms of Movymia given once a day as an injection under the skin of the thigh or abdomen (belly). Patients may inject themselves once they have been trained.

Patients should receive calcium and vitamin D supplements if they do not get enough from their diet. Movymia can be used for up to two years. The two-year course of Movymia should be given only once during a patient’s lifetime.

The medicine can only be obtained with a prescription.

Osteoporosis happens when not enough new bone grows to replace the bone that is naturally broken down. Gradually, the bones become less dense and more likely to break. In women, osteoporosis is more common after the menopause, when the levels of the female hormone oestrogen fall. Osteoporosis can also occur as a side effect of glucocorticoid treatment in men and women.

The active substance in Movymia, teriparatide, is identical to part of the human parathyroid hormone. It acts like the hormone to stimulate bone formation by acting on osteoblasts (bone-forming cells). It also increases the absorption of calcium from food and prevents too much calcium being lost in the urine.

Laboratory studies comparing Movymia with Forsteo have shown that the active substance in Movymia is highly similar to that in Forsteo in terms of structure, purity and biological activity.

Because Movymia is a biosimilar medicine, the studies on effectiveness and safety of teriparatide carried out with Forsteo do not need to be repeated for Movymia. A study in 54 healthy women has shown that the same doses of the two medicines given by injection under the skin produced similar levels of the active substance teriparatide in the body. Further, Movymia and Forsteo produced similar effects on calcium levels in the blood.

The most common side effect with Movymia (seen in more than 1 patient in 10) is pain in the arms or legs. For the full list of all side effects reported with Movymia, see the package leaflet.

Movymia must not be used in patients who have other bone diseases such as Paget’s disease, bone cancer or bone metastases (cancer that has spread to the bone), patients who have had radiation therapy of the skeleton, or patients who have hypercalcaemia (high blood calcium levels), unexplained high levels of alkaline phosphatase (an enzyme) or severe kidney disease. Movymia must not be used during pregnancy or breastfeeding. For the full list of restrictions, see the package leaflet.

The Agency’s Committee for Medicinal Products for Human Use (CHMP) considered evidence showing that Movymia has a highly similar structure, purity and biological activity to Forsteo and is distributed in the body in the same way. This was considered sufficient to conclude that Movymia will behave in the same way in terms of effectiveness and safety. Thus, as for Forsteo, the benefit outweighs the identified risks and the Committee recommended that Movymia be given marketing authorisation.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Movymia have been included in the summary of product characteristics and the package leaflet.

The European Commission granted a marketing authorisation valid throughout the European Union for Movymia on 11 January 2017.

For more information about treatment with Movymia, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

English (EN)
(81.2 KB – PDF)

First published: 16/03/2017Last updated: 16/03/2017

View

English (EN)
(87.49 KB – PDF)

First published: 29/10/2020Last updated: 03/11/2021

View

Product information

English (EN)
(867.16 KB – PDF)

First published: 16/03/2017Last updated: 24/04/2025

View

Latest procedure affecting product information:
VR/0000266969

24/04/2025

This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

Product information documents contain:

summary of product characteristics (annex I);
manufacturing authorisation holder responsible for batch release (annex IIA);
conditions of the marketing authorisation (annex IIB);
labelling (annex IIIA);
package leaflet (annex IIIB).

English (EN)
(32.89 KB – PDF)

First published: 16/03/2017Last updated: 19/06/2019

View

Product details

Name of medicine: Movymia
Active substance: teriparatide
International non-proprietary name (INN) or common name: teriparatide
Therapeutic area (MeSH): Osteoporosis
Anatomical therapeutic chemical (ATC) code: H05AA02

Pharmacotherapeutic group

Calcium homeostasis

Therapeutic indication

Movymia is indicated in adults.

Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and non vertebral fractures but not hip fractures has been demonstrated.

Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.

[ad_2]

Source link

Overview

What is Movymia and what is it used for?

How is Movymia used?

How does Movymia work?

What benefits of Movymia have been shown in studies?

What are the risks associated with Movymia?

Why is Movymia approved?

What measures are being taken to ensure the safe and effective use of Movymia?

Other information about Movymia

Product information

Product details

Pharmacotherapeutic group

Therapeutic indication

Product information – with tracked changes

LEAVE A REPLY Cancel reply